<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="continuously involved in the development of an effective line of" exact="treatment" post="to control the novel coronavirus from spreading rapidly. Worldwide"/>
 <result pre="the development of nucleic acid based therapeutic drugs for the" exact="treatment" post="of SARS-CoV-2. By the introduction of nucleic acid-based therapeutic"/>
 <result pre="inside respiratory tracts but it also helps to causes the" exact="infection" post="in the host cells [13]. The physiological function of"/>
 <result pre="lungs get susceptible to several diseases ranging from common viral" exact="infection" post="to lung cancer. Viruses that infect the respiratory tract"/>
 <result pre="Currently, there is no therapeutic agent or vaccination for the" exact="treatment" post="of SARS-CoV-2. In the present scenario, patients are administrated"/>
 <result pre="therapeutic approach that could help in the control, prevention, and" exact="treatment" post="of SARS-CoV-2 infection is an urgent need to save"/>
 <result pre="could help in the control, prevention, and treatment of SARS-CoV-2" exact="infection" post="is an urgent need to save the entire globe"/>
 <result pre="due to genetic variations from individual to individual. The SARS-CoV-2" exact="infection" post="can be classified into two categories: initial (non-severe) and"/>
 <result pre="initial stages, macrophages and granulocytes mediate the inflammatory responses. SARS-CoV-2" exact="infection" post="in the respiratory system has been reported to activate"/>
 <result pre="cells is that it imitates the protein synthesis during the" exact="infection" post="as the protein remains localized in the plasma membrane,"/>
 <result pre="as aptamers, siRNA, and miRNA have been used for the" exact="treatment" post="of severe viral infections including HIV-1 (human immunodeficiency virus)"/>
 <result pre="Further, it has been reported that the ribozyme inhibited the" exact="infection" post="of influenza virus both in vitro and in vivo"/>
 <result pre="modified ASOs (antisense oligonucleotides) were effective in suppression of the" exact="infection" post="by influenza A/PR8/34 (H1N1) virus [42]. ASOs were also"/>
 <result pre="be effective in the inhibition of RSV (respiratory syncytial virus)" exact="infection" post="[43]. 2.1 DNA vaccines Incorporation of a eukaryotic expression"/>
 <result pre="therapeutic molecules have shown some promising effects against the viral" exact="infection" post="in the respiratory tract and to several other diseases"/>
 <result pre="siRNA. In virus-infected cells, these designed siRNAs significantly inhibited the" exact="infection" post="[128]. In another study, the synthesis of chimeric RNA-DNA"/>
 <result pre="SARS-CoV RNA. Thus found to be a potent and feasible" exact="treatment" post="option for SARS [129]. In the mice models and"/>
 <result pre="advancing with their nucleic acid-based therapeutic models towards its clinical" exact="testing" post="and evaluation [58]. The prime characteristics of the vaccine"/>
 <result pre="like Takis, Karolinska Institute, and Inovio Pharmaceuticals are trying and" exact="testing" post="various entry mechanisms for the DNA vaccines, including the"/>
 <result pre="vaccines that are in different phases of trials for the" exact="treatment" post="of COVID-19. 6 Cost associated with vaccine development and"/>
 <result pre="stability and translation efficacy [161, 162]. The potential risk of" exact="infection" post="and insertion induced mutagenesis are minimized by mRNA based"/>
 <result pre="use against SARS-CoV-2 which can be an effective line of" exact="treatment" post="for various other viral diseases. Declarations Author contribution statement"/>
 <result pre="J. Mol. Med.34199938138410085409 114SenD.GeyerC.R.DNA enzymesCurr. Opin. Chem. Biol.2619986806879914188 115MillerC.M.HarrisE.N.Antisense oligonucleotides:" exact="treatment" post="strategies and cellular internalizationRNA Dis.342016 116MatsukuraM.Phosphorothioate analogs of oligodeoxynucleotides:"/>
 <result pre="target for antiviral developmentAntivir. Res.178202010479232272173 128PyrcK.Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycleAntimicrob. Agents Chemother.50620062000200816723558"/>
</results>
